Test drug HEC73543 against chemo for FLT3-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older when you sign consent.
- You have AML, either from starting in the blood/bone marrow (primary) or AML related to MDS.
- Your AML is resistant to treatment or has relapsed after your first-line AML therapy (even if you had a stem cell transplant).
- Your test results must show the FLT3 mutation—specifically FLT3-ITD—on a central lab blood or bone marrow sample.
- Your day-to-day function must be fairly good (ECOG score 0–2).
- Your doctor must think you can safely receive the planned rescue/salvage chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This Phase 3 study tests whether XY0206 can work better than standard “salvage” chemotherapy in adults whose acute myeloid leukemia (AML) has come back or did not respond to prior treatment. It targets AML with a specific genetic change (FLT3-ITD) and aims to improve outcomes when standard options are limited.
This study tests clifutinib (a targeted medicine) combined with chemotherapy in people newly diagnosed with AML. It aims to see if this combination is safer and more effective, including in older adults and people who may not tolerate strong chemotherapy.
This trial tests a targeted therapy for people with a specific genetic change in their AML cells called FLT3-ITD. It aims to see if adding this targeted drug to standard chemotherapy improves outcomes for patients who are otherwise healthy enough to receive intensive treatment.
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
Hear when a new Leukemia Acute Myeloid - AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.